Silvia Bressan, PhD

Translational Oncology & Immunotherapy Scientist

Cancer Immunotherapy / Biomarker Discovery / CAR-T / Multi-omics

silvi@nbulai.com
employee.nbulai.com / Employee 0006
LinkedIn

Translational immunologist with expertise in cancer immunotherapy, biomarker discovery, patient cohorts, CAR-T development, and multi-omics. Experienced in integrating experimental and computational approaches to translate biological discoveries into therapeutic strategies and clinical hypotheses.

Scientific journey

Current · IOR Switzerland · Padova / USI · VIMM · Padova

Scientist, Translational Oncology and Immunotherapy (2025-present)

Marie Sklodowska-Curie Postdoctoral Fellowship - European Commission (2025-2027)

Postdoctoral Researcher - IOR Bellinzona, Andrea Alimonti Lab (2023-2025)

PhD Molecular Pharmacology - University of Padova / USI cotutelle (2020-2023)

Research Associate - VIMM (2019-2020)

MSc Pharmaceutical Biotechnologies · BSc Biotechnology - University of Padova

Translational highlights

Nectin2 immunotherapy
Target discovery and therapeutic development in prostate cancer
CAR-T / antibody / ADC strategies
Therapeutic development and translational evaluation
Biomarker programs
Patient cohorts + immune profiling + single-cell / spatial / computational analysis

Selected publications

Cancer Cell, 2024
Retinoic acid receptor activation reprograms senescence response and enhances NK anti-tumor activity
Cancer Cell, 2024
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer
Nature Aging, 2024
Targeting senescence with a polyphenol-rich natural extract improves longevity and healthspan in mice
Trends in Cancer, 2026
Prostate cancer: evading immunity, inspiring therapy